Table 5.

All grade 3 or higher AEs and serious AEs in arm C

AEArm C
CPX-351 plus enasidenib (N = 7)
Patients with any grade ≥3 AE by preferred term, n (%) 7 (100) 
Grade ≥3 hematologic AE, n (%)  
Febrile neutropenia 7 (100) 
Thrombocytopenia 6 (86) 
Neutropenia 5 (71) 
Anemia 4 (57) 
Leukopenia 1 (14) 
Grade ≥3 nonhematologic AE, n (%)  
Allergic transfusion reaction 1 (14) 
ALT increased 1 (14) 
Clostridium difficile infection 1 (14) 
Diarrhea 1 (14) 
Drug eruption 1 (14) 
Maculopapular rash 1 (14) 
Streptococcal bacteremia 1 (14) 
Patients with any serious AE by preferred term, n (%) 3 (43) 
Febrile neutropenia 2 (29) 
Pyrexia 1 (14) 
AEArm C
CPX-351 plus enasidenib (N = 7)
Patients with any grade ≥3 AE by preferred term, n (%) 7 (100) 
Grade ≥3 hematologic AE, n (%)  
Febrile neutropenia 7 (100) 
Thrombocytopenia 6 (86) 
Neutropenia 5 (71) 
Anemia 4 (57) 
Leukopenia 1 (14) 
Grade ≥3 nonhematologic AE, n (%)  
Allergic transfusion reaction 1 (14) 
ALT increased 1 (14) 
Clostridium difficile infection 1 (14) 
Diarrhea 1 (14) 
Drug eruption 1 (14) 
Maculopapular rash 1 (14) 
Streptococcal bacteremia 1 (14) 
Patients with any serious AE by preferred term, n (%) 3 (43) 
Febrile neutropenia 2 (29) 
Pyrexia 1 (14) 

All AEs were coded using Medical Dictionary for Regulatory Activities, version 21.1. Multiple entries for an individual patient under each preferred term were only counted once.

ALT, alanine aminotransferase.

or Create an Account

Close Modal
Close Modal